Vetter speakers offer insight into innovative solutions in clinical manufacturing

Why is external manufacturing in clinical development fast becoming a strategic option for innovative pharmaceutical and biotech companies? Find out at BIO 2014.

Why is external manufacturing in clinical development fast becoming a strategic option for innovative pharmaceutical and biotech companies? Find out at BIO 2014.

Partnering with a CDMO for clinical manufacturing offers significant advantages including new technologies, experienced technical staff, and shortened drug development cycles. At the Bio International Conference on 23-26 June in San Diego, two Vetter speakers offer their insight into the strategic value offered by outsourcing clinical manufacturing.

On June 24, at 1:45 pm, Dr Claudia Roth, President of Vetter Development Services USA, will discuss commercial versus clinical manufacturing, use of disposables, selection criteria and other key issues in her presentation 'Strategic Outsourcing in Clinical Development – Innovative Solutions and Design to meet Industry Demand.'

On June 25, at 10:15 am, Troy Carpenter, President at Vetter Pharma International USA, will discuss clinical manufacturing organisations and best practices, including responsibilities for regulations and compliance, and creating positive working relationships in his panel discussion presentation entitled: 'CMO Innovations and Best Practices'.

Presentation

Strategic Outsourcing in Clinical Development – Innovative Solutions and Design to meet Industry Demand

Tuesday, 24 June, 1:45 – 2:45 pm

Room 31C

Dr Claudia Roth, President of Vetter Development Services USA Inc.

Panel Discussion

CMO Innovations and Best Practices

Wednesday, 25 June, 10:15 am – 11:30 am

Room 31C

Troy Carpenter, President at Vetter Pharma International USA Inc.

Companies